Literature DB >> 18344002

Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002.

Joanne E Brady1, Samuel R Friedman, Hannah L F Cooper, Peter L Flom, Barbara Tempalski, Karla Gostnell.   

Abstract

This paper estimates the prevalence of current injection drug users (IDUs) in 96 large U.S. metropolitan statistical areas (MSAs) annually from 1992 to 2002. Multiplier/allocation methods were used to estimate the prevalence of injectors because confidentiality restrictions precluded the use of other commonly used estimation methods, such as capture-recapture. We first estimated the number of IDUs in the U.S. each year from 1992 to 2002 and then apportioned these estimates to MSAs using multiplier methods. Four different types of data indicating drug injection were used to allocate national annual totals to MSAs, creating four distinct series of estimates of the number of injectors in each MSA. Each series was smoothed over time; and the mean value of the four component estimates was taken as the best estimate of IDUs for that MSA and year (with the range of component estimates indicating the degree of uncertainty in the estimates). Annual cross-sectional correlations of the MSA-level IDU estimates with measures of unemployment, hepatitis C mortality prevalence, and poisoning mortality prevalence were used to validate our estimates. MSA-level IDU estimates correlated moderately well with validators, demonstrating adequate convergence validity. Overall, the number of IDUs per 10,000 persons aged 15-64 years varied from 30 to 348 across MSAs (mean 126.9, standard deviation 65.3, median 106.6, interquartile range 78-162) in 1992 and from 37 to 336 across MSAs (mean 110.6, standard deviation 57.7, median 96.1, interquartile range 67-134) in 2002. A multilevel model showed that overall, across the 96 MSAs, the number of injectors declined each year until 2000, after which the IDU prevalence began to increase. Despite the variation in component estimates and methodological and component data set limitations, these local IDU prevalence estimates may be used to assess: (1) predictors of change in IDU prevalence; (2) differing IDU trends between localities; (3) the adequacy of service delivery to IDUs; and (4) infectious disease dynamics among IDUs across time.

Entities:  

Mesh:

Year:  2008        PMID: 18344002      PMCID: PMC2329751          DOI: 10.1007/s11524-007-9248-5

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  38 in total

1.  Gen-X junkie: ethnographic research with young White heroin users in Washington, DC.

Authors:  T G Pierce
Journal:  Subst Use Misuse       Date:  1999-12       Impact factor: 2.164

2.  Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence.

Authors:  S R Friedman; T Perlis; D C Des Jarlais
Journal:  Am J Public Health       Date:  2001-05       Impact factor: 9.308

3.  Differences in severity of heroin dependence by route of administration: the importance of length of heroin use.

Authors:  G Barrio; L De La Fuente; C Lew; L Royuela; M J Bravo; M Torrens
Journal:  Drug Alcohol Depend       Date:  2001-07-01       Impact factor: 4.492

4.  Estimating prevalence of problem drug use at national level in countries of the European Union and Norway.

Authors:  Ludwig Kraus; Rita Augustin; Martin Frischer; Petra Kümmler; Alfred Uhl; Lucas Wiessing
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

5.  A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States.

Authors:  Salaam Semaan; Don C Des Jarlais; Ellen Sogolow; Wayne D Johnson; Larry V Hedges; Gilbert Ramirez; Stephen A Flores; Lisa Norman; Michael D Sweat; Richard Needle
Journal:  J Acquir Immune Defic Syndr       Date:  2002-07-01       Impact factor: 3.731

6.  A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain.

Authors:  M Frischer; M Hickman; L Kraus; F Mariani; L Wiessing
Journal:  Addiction       Date:  2001-10       Impact factor: 6.526

Review 7.  Heroin overdose: causes and consequences.

Authors:  M Warner-Smith; S Darke; M Lynskey; W Hall
Journal:  Addiction       Date:  2001-08       Impact factor: 6.526

8.  Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.

Authors:  D D Celentano; N Galai; A K Sethi; N G Shah; S A Strathdee; D Vlahov; J E Gallant
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

9.  Estimating the size of hard-to-reach populations: a novel method using HIV testing data compared to other methods.

Authors:  C P Archibald; G C Jayaraman; C Major; D M Patrick; S M Houston; D Sutherland
Journal:  AIDS       Date:  2001-04       Impact factor: 4.177

10.  Estimating the relative incidence of heroin use: application of a method for adjusting observed reports of first visits to specialized drug treatment agencies.

Authors:  M Hickman; S Seaman; D de Angelis
Journal:  Am J Epidemiol       Date:  2001-04-01       Impact factor: 4.897

View more
  71 in total

1.  Estimates of the population prevalence of injection drug users among hispanic residents of large US metropolitan areas.

Authors:  Enrique R Pouget; Samuel R Friedman; Charles M Cleland; Barbara Tempalski; Hannah L F Cooper
Journal:  J Urban Health       Date:  2012-06       Impact factor: 3.671

2.  Drug arrests and injection drug deterrence.

Authors:  Samuel R Friedman; Enrique R Pouget; Sudip Chatterjee; Charles M Cleland; Barbara Tempalski; Joanne E Brady; Hannah L F Cooper
Journal:  Am J Public Health       Date:  2010-12-16       Impact factor: 9.308

3.  Use of Medicaid data to explore community characteristics associated with HIV prevalence among beneficiaries with schizophrenia.

Authors:  James Walkup; Ayse Akincigil; Donald R Hoover; Michele J Siegel; Shahla Amin; Stephen Crystal
Journal:  Public Health Rep       Date:  2011 Sep-Oct       Impact factor: 2.792

4.  Female and male differences in AIDS diagnosis rates among people who inject drugs in large U.S. metro areas from 1993 to 2007.

Authors:  Brooke S West; Enrique R Pouget; Barbara Tempalski; Hannah L F Cooper; H Irene Hall; Xiaohong Hu; Samuel R Friedman
Journal:  Ann Epidemiol       Date:  2015-02-07       Impact factor: 3.797

5.  Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992--2002): estimation methods and prevalence trends.

Authors:  Hannah L F Cooper; Joanne E Brady; Samuel R Friedman; Barbara Tempalski; Karla Gostnell; Peter L Flom
Journal:  J Urban Health       Date:  2008-08-16       Impact factor: 3.671

6.  HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002.

Authors:  Barbara Tempalski; Spencer Lieb; Charles M Cleland; Hannah Cooper; Joanne E Brady; Samuel R Friedman
Journal:  J Urban Health       Date:  2008-11-18       Impact factor: 3.671

7.  The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA.

Authors:  Carl A Latkin; Deborah Donnell; David Metzger; Susan Sherman; Apinun Aramrattna; Annet Davis-Vogel; Vu Minh Quan; Sharavi Gandham; Tasanai Vongchak; Tom Perdue; David D Celentano
Journal:  Soc Sci Med       Date:  2008-12-13       Impact factor: 4.634

8.  The entry of Colombian-sourced heroin into the US market: the relationship between competition, price, and purity.

Authors:  Daniel Rosenblum; George Jay Unick; Daniel Ciccarone
Journal:  Int J Drug Policy       Date:  2013-10-19

9.  Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York.

Authors:  Jason Kessler; Julie E Myers; Kimberly A Nucifora; Nana Mensah; Christopher Toohey; Amin Khademi; Blayne Cutler; Scott Braithwaite
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

10.  Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening.

Authors:  R Irvin; A McAdams-Mahmoud; D Hickman; J Wilson; W Fenwick; I Chen; N Irvin; O Falade-Nwulia; M Sulkowski; R Chaisson; D L Thomas; S H Mehta
Journal:  J Community Med Health Educ       Date:  2016-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.